University of Leicester

RS Oncology Data for Novel Treatment of Aggressive Cancers Selected for an Oral Presentation at ASCO Annual Meeting

Retrieved on: 
Wednesday, May 1, 2024
Radiology, Biotechnology, Pharmaceutical, Oncology, Health, Infectious Diseases, Hospitals, Clinical Trials, University, Mesothelioma, Cancer, EDT, Kidney, Safety, Malignant pleural effusion, Stomach, Breast, Growth, ASCO, Patient, MPE, Society, Lung, Trial of the century, Clinical trial, Annual general meeting, University of Leicester, Pharmaceutical industry

RS Oncology , a clinical-stage biopharmaceutical company focused on developing novel treatments for aggressive and rare cancers, today announced that it will present the complete Phase 1 dose escalation data as an oral presentation at the world’s largest oncology meeting, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • RS Oncology , a clinical-stage biopharmaceutical company focused on developing novel treatments for aggressive and rare cancers, today announced that it will present the complete Phase 1 dose escalation data as an oral presentation at the world’s largest oncology meeting, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The MITOPE phase 1 multicenter study, ( clinical trials.gov #NCT05278975 ) investigating the safety and tolerability of RSO-021, is a first-in-human trial.
  • RSO-021 is a first-in-class therapy for treatment of mesothelioma and solid tumors in patients with malignant pleural effusion.
  • Aggressive cancers present tremendous challenges in treatment and management, primarily due to rapid growth and spread to other parts of the body.

Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy

Retrieved on: 
Wednesday, April 10, 2024
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, FDA, Congress, Immunoglobulin G, ALPN, University, Glomerular filtration rate, Proteinuria, Survival, Cytokine, MD, Hematuria, UPCR, Webcast, Immunoglobulin A, EGFR, Disease, Nephrology, Patient, WCN, Alpine, Inflammation, Multimedia, Infection, Biomarker, Exhibition, University of Leicester, Autoimmunity, BAFF, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, including IgA nephropathy, where povetacicept is administered subcutaneously (SC) once every four weeks.
  • As of March 01, 2024, 41 patients with IgAN had received povetacicept 80 or 240 mg subcutaneously every 4 weeks.
  • These data strongly support the inhibition of APRIL/BAFF pathways by povetacicept and its efficacy in the treatment of IgAN as well as the need for further clinical development.

ATLAS OCEAN VOYAGES INTRODUCES NEW CULTURAL EXPEDITION PROGRAMMING FOR 2024

Retrieved on: 
Thursday, March 7, 2024
Museum, Social work, Royal Horticultural Society, Architecture, Doctor of Philosophy, Royal, Culture, Medical microbiology, Scott Polar Research Institute, University, RSPB, Religious broadcasting, Victoria and Albert Museum, Fossil, Local government, Atlas, British Museum, Fellow, Plant, University of Leicester, MBA, Radio, Gardening, BBC, Economics, Disabled parking permit, Environmental science, Education, Pepperdine University, FPV, Pritikin diet, Life, American Red Cross, Physics, Exploration, Research, Collection, Politics, Royal Society, University of Cambridge, Radio 4, Arawak, Emeritus, Imperial College London, Carib, WSI, Geological Society of London, UC, Emmanuel College, RHS, Tourism

FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season. An addition to the company's year-round expeditions that include Polar and Epicurean Expeditions, these new programs enhance appreciation for a variety of captivating regions and local cultures.

Key Points: 
  • FORT LAUDERDALE, Fla., March 7, 2024 /PRNewswire/ -- Atlas Ocean Voyages announces a collection of expert-led workshops and onboard lecturers as part of the 2024 Cultural Expeditions season.
  • Atlas Ocean Voyages Cultural Expeditions include onboard and onshore programming focused on drone and photo workshops, cooking culture, and destination experts.
  • Below is an overview for 2024:
    Guests will embark on an exhilarating journey exclusively with Atlas Ocean Voyages Cultural Expeditions' new Atlas Focus Lab: Drone & Photo Workshops.
  • Combining an intimate and luxurious environment with genuine hospitality, Atlas Ocean Voyages ensures that each journey is a once-in-a-lifetime expedition.

Metrus Energy Adds John Hamilton as VP of Legal and Kieran James as VP of Commercial Operations

Retrieved on: 
Tuesday, January 16, 2024
Stanford University, JD/MBA, SAN, University, Air force, SunPower, Winston & Strawn, Investment, University of Leicester, Growth, Management

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Metrus Energy, a market leader in climate-positive investing, announced today the hiring of John Hamilton as Vice President of Legal and Kieran James as Vice President of Commercial Operations.

Key Points: 
  • Metrus Energy has hired industry veterans John Hamilton as Vice President of Legal and Kieran James as Vice President of Commercial Operations.
  • SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Metrus Energy, a market leader in climate-positive investing, announced today the hiring of John Hamilton as Vice President of Legal and Kieran James as Vice President of Commercial Operations.
  • "With the addition of John and Kieran, we are well-positioned to further scale and cater to the rapidly growing Energy-as-a-Service market," said Bob Hinkle, Founder and Executive Chairman, Metrus Energy.
  • "We are thrilled to welcome two highly skilled industry veterans, John and Kieran, to Metrus," said Bob Hinkle, Founder and Executive Chairman of Metrus Energy.

EcoEngineers Welcomes Laith Amin as Vice President, Growth and Strategic Development

Retrieved on: 
Thursday, December 14, 2023
Environmental Health, Professional Services, Other Natural Resources, Natural Resources, Other Energy, Utilities, Climate Change, Coal, Alternative Energy, Engineering, Energy, Green Technology, Manufacturing, Sustainability, Environmental, Social and Governance (ESG), Environment, Consulting, Carbon, BECCS, CCUS, Henley Business School, Economics, Laith, Honours degree, Multimedia, Blockchain, CDR, Rio Tinto, Carbon capture and storage, DNV, Growth, Digital United, University of Leicester, ESG, Management

Clean energy consulting, auditing, and advisory firm, EcoEngineers , has announced the addition of Laith Amin to the executive team as vice president, growth and strategic development.

Key Points: 
  • Clean energy consulting, auditing, and advisory firm, EcoEngineers , has announced the addition of Laith Amin to the executive team as vice president, growth and strategic development.
  • Amin brings more than 20 years of international experience driving transformation and growth through business development, account management, sales, and strategy with an emphasis on decarbonization.
  • View the full release here: https://www.businesswire.com/news/home/20231214459011/en/
    Laith Amin joins EcoEngineers as vice president, growth and strategic development.
  • (Photo: Business Wire)
    Amin has a proven track record in the development of new markets, products, and technologies to create differentiation and margin lift.

Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, University of Leicester, Survival, FRCP, ALPN, GN, EGFR, Biomarker, Fig, Nephrology, PMN, MD, Inflammation, Cytokine, Doctor of Philosophy, Glomerular filtration rate, Immunoglobulin A, American Society of Nephrology, Multimedia, Society, BAFF, Glossary of education terms (G–L), Disease, Barratt, ASN, Webcast, Emory University School of Medicine, University, Immunoglobulin G, Autoimmunity, Glomerulonephritis, Patient, Infection, Vaccine, Sewage treatment, Pharmaceutical industry, Research, IgA nephropathy, Proteinuria, Alpine, Medicine, UPCR

RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.

Key Points: 
  • RUBY-3 is a multiple ascending dose, multi-cohort, open label, phase 1b/2a study of povetacicept in autoimmune glomerulonephritis, where povetacicept is administered subcutaneously (SC) once every four weeks for up to 48 weeks.
  • A higher dose of povetacicept, 240 mg SC every four weeks, continues to enroll, with initial data expected in 1H 2024.
  • A higher dose of povetacicept 240 mg every four weeks is currently being explored and will be of great interest.
  • “We eagerly await the initial data from the next 240 mg dose level in the first half of 2024.

Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual Meeting

Retrieved on: 
Friday, October 13, 2023
FRCP, Barratt, Abstract, COVID, Nephrology, Society, University, Therapy, ASN, Tetanus, University of Leicester, Diphtheria, American Society of Nephrology, Serum, Patient, Infection, Pharmaceutical industry, IgA nephropathy

BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company’s product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA.

Key Points: 
  • Additional analysis of week 36 data from Phase 2b ORIGIN study show atacicept 150mg reduces serum Gd-IgA1, supporting atacicept’s potential as long-term disease-modifying IgAN therapy
    Atacicept showed continued protective titers to diphtheria and tetanus and balanced COVID infections vs. placebo in IgAN
    BRISBANE, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that three abstracts on the Company’s product candidate atacicept in immunoglobulin A nephropathy (IgAN) have been selected for poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023, which is taking place November 2–5, 2023, in Philadelphia, PA.
    Kidney Week Poster Presentation Details:
    Jonathan Barratt, Ph.D., FRCP, The Mayer Professor of Renal Medicine, University of Leicester, UK

His Excellency Dr. Hassan Al Muhairi, Assistant Undersecretary for the Curriculum Sector, inaugurates the proceedings of the UAE's grandest educational event

Retrieved on: 
Wednesday, October 11, 2023
University, Education, Cloud, Parent, Multimedia, Informa, University of Sharjah, Student, Comic book convention, School, University of Debrecen, Zayed University, Abu Dhabi National Exhibition Centre, University of Waterloo, Curriculum, University of Guelph, University of New Brunswick Faculty of Law, American University, American University of Sharjah, Ministry, Iowa State University, Excellency, University of Leicester, St. Cloud State University, Assistant, United Arab Emirates University, Higher Colleges of Technology, Learning, Tutoring

This year’s event has attracted thousands of school and college students seeking the latest opportunities in higher education.

Key Points: 
  • This year’s event has attracted thousands of school and college students seeking the latest opportunities in higher education.
  • View the full release here: https://www.businesswire.com/news/home/20231011003257/en/
    His Excellency Dr. Hassan Al Muhairi, Assistant Undersecretary for the Curriculum Sector, inaugurates the proceedings of the UAE's grandest educational event (Photo: Business Wire)
    Commenting on the event, His Excellency Al Muhairi underscored the Ministry's unwavering commitment to offering students the finest educational avenues.
  • He emphasized the Ministry's dedication to enlightening students about the promising prospects in the evolving education and learning landscape.
  • Furthermore, he expressed the Ministry's determination to facilitate students' pursuit of higher education by enabling them to access the most prestigious educational institutions domestically and internationally.

Alacrita Consulting Promotes Saadia Basharat & Jess Hearn-Messenger to Principals

Retrieved on: 
Thursday, October 5, 2023
Jess, University of Leicester, Doctor of Philosophy, Lead, Imperial College London, Health informatics, Master of Science, Therapy, WMG, University of Warwick, University, Systems biology, Growth, VCS, Biochemistry, Monte Carlo, Pharmaceutical industry, Nursing, Neuroendocrinology, Saadia Gaon, Molecular medicine

LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.

Key Points: 
  • LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.
  • In recognition of her successful transition to San Diego, as Alacrita's Head of West Coast Consulting, she has been made a Principal of the firm.
  • We are delighted to promote her to Principal," said Alastair Southwell, Managing Partner at Alacrita Consulting.
  • Additional information on Saadia Basharat, PhD, Principal: https://www.alacrita.com/consultants/saadia-basharat
    Additional information on Jess Hearn-Messenger, PhD, Principal: https://www.alacrita.com/consultants/jess-hearn-messenger

Alacrita Consulting Promotes Saadia Basharat & Jess Hearn-Messenger to Principals

Retrieved on: 
Thursday, October 5, 2023
Jess, University of Leicester, Doctor of Philosophy, Lead, Imperial College London, Health informatics, Master of Science, Therapy, WMG, University of Warwick, University, Systems biology, Growth, VCS, Biochemistry, Monte Carlo, Pharmaceutical industry, Nursing, Neuroendocrinology, Saadia Gaon, Molecular medicine

LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.

Key Points: 
  • LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.
  • In recognition of her successful transition to San Diego, as Alacrita's Head of West Coast Consulting, she has been made a Principal of the firm.
  • We are delighted to promote her to Principal," said Alastair Southwell, Managing Partner at Alacrita Consulting.
  • Additional information on Saadia Basharat, PhD, Principal: https://www.alacrita.com/consultants/saadia-basharat
    Additional information on Jess Hearn-Messenger, PhD, Principal: https://www.alacrita.com/consultants/jess-hearn-messenger